Origin and development of RUTI, a new therapeutic vaccine against mycobacterium tuberculosis infection;Origen y desarrollo de RUTI, una nueva vacuna terapéutica contra la infección por Mycobacterium tuberculosis

Archivos de Bronconeumologia

Volumn 42, Issue 1, 2006, Pages 25-32

  Cardona, P J ^a   Amat, I ^b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b NONE

Author keywords

Chemotherapy; Experimental models; Foamy macrophages; Immunotherapy; Koch phenomenon; Latent bacilli; Mycobacterium tuberculosis; Th1 Th2; Tolerance

Indexed keywords

ANTIGEN; BCG VACCINE; RUTI VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; BACILLUS; CELL CYCLE; CHEMOTHERAPY; DISEASE COURSE; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; GRANULOMA; GUINEA PIG; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MACROPHAGE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NECROSIS; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; TH1 CELL; TH2 CELL; TH3 CELL; TUBERCULOSIS;

EID: 32844475710     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13083277     Document Type: Review

References (63)

1. World Health Organization. Global Tuberculosis Control: surveillance, planning, financing. Geneva: WHO Report; 2004.
2. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221-S47.
3. Centers for Disease Control and Prevention. Development of new vaccines for tuberculosis. Recommendations of the Advisory Council for the Elimination of Tuberculosis (ACET). MMWR Recomm Rep. 1998;47:1-6.
4. Bloom DC. HSV LAT and neuronal survival. Int Rev Immunol. 2004;23:187-98.
5. Mason CA, Egli T. Dynamics of microbial growth in the decelerating and stationary phase of batch culture. En: Kjelleberg S, editor. Starvation in bacteria. New York: Plenum Press; 1993. p. 81-102.
6. Hengge-Aronis R. The role of rpoS in early stationary-phase gene regulation in Escherichia coli K12. En: Kjelleberg S, editor. Starvation in bacteria. New York: Plenum Press; 1993. p. 171-200.
7. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998;393:537-44.
8. Brennan PJ. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb). 2003;83:91-7.
9. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tu-berculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3:S231-79.
10. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle. 1985;66:219-25.
11. Corper HJ, Cohn ML. The viability and virulence of old cultures of tubercle bacilli: studies on twelve-year broth cultures maintained at incubator temperature. Am Rev Tuberc. 1933;28:856-74.
12. Canetti G. Exogenous reinfection: its relative impact with regard to development of pulmonary tuberculosis. A study of the pathology. Tubercle. 1950;31:224-33.
13. Opie EL, Aronson JD. Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculous lesions. Arch Pathol. 1927;4:121.
14. McCune RM, Tompsett R, McDermott W. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug susceptible bacilli in the tissues despite prolonged antimicrobial therapy. J Exp Med. 1956;104:737-62.
15. Kaprelyants AS, Gottschal JC, Kell DB. Dormancy in non-sporulating bacteria. FEMS Microbiol Rev. 1993;10:271-85.
16. Shleeva MO, Bagramyan K, Telkov MV, Mukamolova GV, Young M, Kell DB, et al. Formation and resuscitation of "non-culturable" cells of Rhodococcus rhodochrous and Mycobacterium tuberculosis in prolonged stationary phase. Microbiology. 2002;148:1581-91.
17. Koch AL. Microbial physiology and ecology of slow growth. Microbiol Mol Biol Rev. 1997;61:305-18.
18. Wayne LG. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur J Clin Microbiol Infect Dis. 1994;13:908-14.
19. Wayne LG, Lin KY. Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect Immun. 1982;37:1042-9.
20. McKinney JD, Honer ZU, Bentrup K, Muñoz-Elias EJ, Miczak A, Chen B, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature. 2000;406:735-8.
21. Orme IM. The latent tuberculosis bacillus (I'll let you know if I ever meet one). Int J Tuberc Lung Dis. 2001;5:589-93.
22. Wallis RS, Patil S, Cheon SH, Edmonds K, Phillips M, Perkins MD, et al. Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1999;43:2600-6.
23. Mattman KH, Tunstall KH, Mathews WW, Gordon DL. L variation in mycobacteria. Am Rev Respir Dis. 1960;82:202-11.
24. Mattman LH. Cell wall deficient forms. Stealth pathogens. Boca Ratón: CRC Press; 2001.
25. Cardona PJ, Llatjós R, Gordillo S, Díaz J, Ojanguren I, Ariza A, et al. Evolution of granulomas in mice infected aerogenically with Mycobacterium tuberculosis. Scan J Immunol. 2000;52:156-63.
26. Cardona PJ, Ausina V. Histopatología de la tuberculosis. Aproximación a la evolución de las lesiones pulmonares en modelos de experimentación animal inducidos mediante aerosol. Arch Bronconeumol. 2000;36:645-50.
27. Green GM. Alveolobronchiolar transport mechanisms. Arch Intern Med. 1973;131:109-14.
28. Lefford MJ. Diseases in mice and rats. En: Kubica GP, Wayne LG, editors. The mycobacteria: a source book. New York: Marcel Dekker Inc.; 1984; p. 947-77.
29. Cardona PJ, Gordillo S, Amat I, Díaz J, Lonca J, Vilaplana C, et al. Catalase-peroxidase activity has no influence on virulence in a murine model of tuberculosis. Tuberculosis (Edinb). 2003;83:351-9.
30. Cardona PJ, Cooper A, Luquin M, Ariza A, Filipo F, Orme IM, et al. The intravenous model of murine tuberculosis is less pathogenic than the aerogenic model owing to a more rapid induction of systemic immunity. Scand J Immunol. 1999;49:362-6.
31. Dunn PL, North RJ. Virulence ranking of some Mycobacterium tuberculosis and Mycobacterium bovis strains according to their ability to multiply in the lungs, induce lung pathology, and cause mortality in mice. Infect Immun. 1995;63:3428-37.
32. Andersen P. Host responses and antigens involved in protective immunity to Mycobacterium tuberculosis. Scand J Immunol. 1997;45:115-31.
33. Grange JM. Immunophysiology and immunopathology of tuberculosis. En: Davies PDO, editor. Clinical tuberculosis. London: Chapman & Hall; 1998. p. 113-27.
34. Dannenberg AM Jr. Rabbit model of tuberculosis. En: Bloom BR, editor. Tuberculosis: pathogenesis, protection, and control. Washington DC: American Society for Microbiology; 1994;10:149-56.
35. Lurie MB. The correlation between the histological changes and the fate of living tubercle bacilli in the organs of tuberculous rabbits. J Exp Med. 1932;55:31-58.
36. Rook GA, Al Attiyah R. Cytokines and the Koch phenomenon. Tubercle. 1991;72:13-20.
37. Shwartzman G. Phenomenon of local tissue reactivity and its immunological, pathological and clinical significance. New York: Paul B. Hober; 1937.
38. Cardona PJ, Llatjós R, Gordillo S, Viñado B, Díaz J, Ariza A, et al. Towards a "human-like" model of tuberculosis: local inoculation of LPS in lungs of Mycobacterium tuberculosis aerogenically infected mice induces intragranulomatous necrosis. Scand J Immunol. 2001;53:65-71.
39. Dannenberg AM Jr. Delayed-type hypersensitivity and cell-mediated immunity in the pathogenesis of tuberculosis. Immunol Today. 1991;12:228-33.
40. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med. 1993;178:2243-7.
41. Comstock GW, Edwards LB, Philip RN, Winn WA. A comparison in the United States of America of tuberculins PPD and RT23. WHO Bull. 1964;31:2-45.
42. Baldwin SL, D'Souza C, Roberts AD, Kelly BP, Frank AA, Lui MA, et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect Immun. 1998;66:2951-9.
43. Costello AM, Kumar A, Narayan V, Akbar MS, Ahmed S, Abou-Zeid C, et al. Does antibody to mycobacterial antigens, including lipoarabinomannan, limit dissemination in childhood tuberculosis? Trans R Soc Trop Med Hyg. 1992;86:686-92.
44. Sánchez-Rodríguez C, Estrada-Chávez C, García-Vigil J, Laredo-Sánchez F, Halabe-Cherem J, Pereira-Suárez A, et al. An IgG antibody response to the antigen 85 complex is associated with good outcome in Mexican Totonaca Indians with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2002;6:706-12.
45. Rook GA, Hernández-Pando R, Dheda K, Teng Seah G. IL-4 in tuberculosis: implications for vaccine design. Trends Immunol. 2004;25:483-8.
46. Meylan PRA, Richman DD, Konbluth RS. Reduced intracellular growth of mycobacteria in human macrophages cultivated at physiologic oxygen pressure. Am Rev Respir Dis. 1992;145:947-53.
47. Park MK, Myers RA, Marzella L. Oxygen tensions and infections: modulation of microbial growth, activity of antimicrobial agents, and immunologic responses. Clin Infect Dis. 1992;14:720-40.
48. Pérez-Padilla R, Franco-Marina F. The impact of altitude on mortality from tuberculosis and pneumonia. Int J Tuberc Lung Dis. 2004;8:1315-20.
49. Vargas MH, Furuya ME, Pérez-Guzmán C. Effect of altitude on the frequency of pulmonary tuberculosis. Int J Tuberc Lung Dis. 2004;8:1321-4.
50. Harmon KR, Marinelli WA, Henke CA, Bitterman PB. Regulation of cell replication, En: Crystal RG, West JB, Barnes PJ, Cherniack NS, Weibel ER, editors. The lung: scientific foundations. New York: Raven Press, Ltd.; 1991. p. 105-29.
51. Seiler P, Ulrichs T, Bandermann S, Pradl L, Jorg S, Krenn V, et al. Cell-wall alterations as an attribute of Mycobacterium tuberculosis in latent infection. J Infect Dis. 2003;188:1326-31.
52. Sturgill-Koszycki S, Schlesinger PH, Chakraborty P, Haddix PL, Collins HL, Fok AK, et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science. 1994;263:678-81.
53. Wallace JG. The heat resistance of tubercle bacilli in the lungs of infected mice. Am Rev Respir Dis. 1961;83:866-71.
54. Ramachandra L, Noss E, Boom WH, Harding CV. Processing of Mycobacterium tuberculosis antigen 85B involves intraphagosomal formation of peptide-major histocompatibility complex II complexes and is inhibited by live bacilli that decrease phagosome maturation. J Exp Med. 2001;194:1421-32.
55. Moreno E, Pizarro-Cerdá J. Life and death of Brucella within cells. En: Govel JP, editor. Intracellular pathogens in membrane interactions and vacuole biogenesis. Georgetown: Eureka.com and Kluwer Academic/Plenum Publishers; 2004. p. 99-129.
56. Gross A, Terraza A, Ouahrani-Bettache S, Liautard JP, Dornand J. In vitro Brucella suis infection prevents the programmed cell death of human monocytic cells. Infect Immun. 2000;68:342-51.
57. Cardona PJ, Gordillo S, Díaz J. Tapia G, Amat I, Pallarés A, et al. Widespread bronchogenic dissemination makes DBA/2 mice more susceptible than C57BL/6 mice to experimental aerosol infection with Mycobacterium tuberculosis. Infect Immun. 2003;71:5845-54.
58. Scanga CA, Mohan VP, Yu K, Joseph H, Tanaka K, Chan J, Flynn JL. Depletion of CD4(+) T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon gamma and nitric oxide synthase 2. J Exp Med. 2000;192:347-58.
59. Rhoades ER, Orme IM. Susceptibility of a panel of virulent strains of Mycobacterium tuberculosis to reactive nitrogen intermediates. Infect Immun. 1997;65:1189-95.
60. Stumbles PA, McWilliam AS, Holt PG. Dendritic cells and mucosal macrophages. En: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, editors. Mucosal immunology. San Diego: Academic Press; 1999. p. 397-412.
61. Cardona PJ, Julián E, Vallés X, Gordillo S, Muñoz M, Luquin M, et al. Production of antibodies against glycolipids from the Mycobacterium tuberculosis cell wall in aerosol murine models of tuberculosis. Scand J Immunol. 2002;55:639-45.
62. Cardona PJ, Amat I, Gordillo S, Arcos V, Guirado E, Díaz J, et al. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine. 2005;23:1393-8.
63. Bolin CA, Whipple DK, Khanna KV, Risdahl JM, Peterson PK, Molitor TW. Infection of swine with Mycobacterium bovis as a model of human tuberculosis. J Infect Dis. 1997;176:1559-66.